Autolus Therapeutics (AUTL) Tops Q2 EPS by 5c

Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.18), $0.05 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $12.91 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.

You May Also Be Interested In

• Apple has talked to PrismML about ways it could use its technology - The Information
• Bernstein downgrades Salesforce, cites lack of evidence for Agentforce momentum
• Benchmark Reiterates Hold Rating on Netflix (NFLX) Ahead of Q2 Results